Infinity Pharmaceuticals Provides Company Update and First Quarter 2019 Financial Results

Wednesday, May 8, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

-- MARIO-275 Phase 2 Study in I/O Nave Urothelial Cancer Patients on Track to Initiate in 2Q19 --

INFINITY PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

Three Months Ended March 31,

2019

2018

Collaboration revenue

$

2,000

$

Royalty revenue

142

Total revenues

2,142

Operating expenses:

Research and development

5,766

5,911

General and administrative

3,398

3,606

Royalty expense

6,761

Total operating expenses

15,925

9,517

Loss from operations

(13,783)

(9,517)

Other income (expense):

Investment and other income

289

159

Interest expense

(304)

(93)

Total other income (expense)

(15)

66

Loss before income taxes

(13,798)

(9,451)

Income taxes benefit

54

Net loss

$

(13,744)

$

(9,451)

Basic and diluted loss per common share:

$

(0.24)

$

(0.18)

Basic and diluted weighted average number of common shares outstanding:

56,924,914

51,883,570



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store